Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: paclitaxel plus trastuzumab
Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Collaborators: Bristol-Myers Squibb|Roche Pharma AG